| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | BRD8958 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.01 | 0.8 |
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | 0.054 | 0.8 |